A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs KD 025 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Kadmon Corporation
  • Most Recent Events

    • 15 May 2017 According to a Kadmon media release, initial data from this trial are expected in Q4 2017.
    • 22 Mar 2017 According to a Kadmon media release, the company expects completion of enrollment in this trial by mid-2017 and expects to report data from this trial no later than fourth quarter of 2017.
    • 03 Jun 2016 According to Kadmon Corporation media release, the first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top